BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 32404114)

  • 1. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
    Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
    Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant radiotherapy improves overall survival for T3/4N+M0 rectal cancer patients: a population-based study of 20300 patients.
    Zhao F; Wang J; Yu H; Cheng X; Li X; Zhu X; Xu X; Lin J; Chen X; Yan S
    Radiat Oncol; 2020 Feb; 15(1):49. PubMed ID: 32103755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
    Amin S; Baine M; Meza J; Lin C
    BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Zou Y; Gao S; Yu X; Zhou T; Xie Y; Guo X; An R; Wang X; Zhao T; Chang A; Gao C; Yu J; Hao J
    Int J Surg; 2023 Jun; 109(6):1573-1583. PubMed ID: 37132194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of radiotherapy for pancreatic malignancies: a population-based analysis of the SEER database.
    Luo Y
    Clin Transl Oncol; 2022 Jan; 24(1):76-83. PubMed ID: 34219204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis.
    Chen X; Liu G; Wang K; Chen G; Sun J
    Oncotarget; 2017 Jul; 8(29):47831-47840. PubMed ID: 28599299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer.
    Zhai Z; Zheng Y; Yao J; Liu Y; Ruan J; Deng Y; Zhou L; Zhao P; Yang S; Hu J; We B; Wu Y; Zhang D; Kang H; Dai Z
    JAMA Netw Open; 2020 Nov; 3(11):e2021881. PubMed ID: 33211105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis.
    Kamarajah SK; Sonnenday CJ; Cho CS; Frankel TL; Bednar F; Lawrence TS; Nathan H
    Ann Surg; 2021 Mar; 273(3):587-594. PubMed ID: 30817352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis.
    Li Y; Liu W; Zhao L; Xu Y; Yan T; Yang Q; Pei Q; Güngör C
    Med Sci Monit; 2020 May; 26():e921515. PubMed ID: 32358953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
    Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
    Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of radiotherapy impact on survival in resected stage I/II pancreatic cancer patients: a population-based study.
    Han D; Gao F; Liu JL; Wang H; Fu Q; Yang GW
    BMC Cancer; 2021 May; 21(1):560. PubMed ID: 34001035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study.
    Zhang Y; Xu G; Chen M; Wei Q; Zhou T; Chen Z; Shen M; Wang P
    Front Oncol; 2020; 10():1018. PubMed ID: 32766130
    [No Abstract]   [Full Text] [Related]  

  • 15. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.
    Cattrini C; Cerbone L; Rubagotti A; Zinoli L; Latocca MM; Messina C; Zanardi E; Boccardo F
    Clin Genitourin Cancer; 2019 Aug; 17(4):e724-e732. PubMed ID: 31160193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study.
    Pu N; Wu W; Liu S; Xie Y; Yin H; Chen Q; He T; Xu Z; Wang W; Yu J; Liu L; Lou W
    Int J Surg; 2023 Oct; 109(10):3137-3146. PubMed ID: 37418574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.
    Jiang W; Haque W; Verma V; Butler EB; Teh BS
    Acta Oncol; 2019 Sep; 58(9):1259-1266. PubMed ID: 31237185
    [No Abstract]   [Full Text] [Related]  

  • 19. Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: an analysis of the surveillance, epidemiology, and end results registry.
    Worni M; Akushevich I; Gloor B; Scarborough J; Chino JP; Jacobs DO; Hahn SM; Clary BM; Pietrobon R; Shah A
    Ann Surg Oncol; 2012 Apr; 19(4):1316-23. PubMed ID: 22002799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.